Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Early sunburn treatment with certain inhibitors may reduce skin cancer risk.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

HDAC inhibitors help brain cells grow and improve brain function.

M50054 may help treat hepatitis and hair loss from chemotherapy.

Nirogacestat can cause severe skin issues like hidradenitis suppurativa.

The compound 4c effectively inhibits the enzyme linked to hair loss.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Terbinafine effectively treated kerion celsi despite disrupted immune responses.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Statins may help treat alopecia areata by reducing harmful immune interactions.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.